We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

American Breast Laser Ablation Therapy Evaluation (ABLATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00807924
Recruitment Status : Unknown
Verified September 2020 by Novian Health Inc..
Recruitment status was:  Recruiting
First Posted : December 12, 2008
Last Update Posted : September 9, 2020
Information provided by (Responsible Party):
Novian Health Inc.

Brief Summary:
The purpose of this patient tracking program is to monitor long term safety and effectiveness of the Novilase™ device and method in real world application.

Condition or disease
Benign Breast Conditions; Breast Fibroadenomas

Detailed Description:
ABLATE is a prospective, observational multi-center tracking database which will evaluate clinical outcomes from patients undergoing Novilase for benign breast conditions (i.e. fibroadenomas, papillomas, etc). Data captured will assess the potential advantages and disadvantages of the procedure as compared with lumpectomy. Tumor characteristics, equipment used, complications, patient satisfaction and cosmesis ratings will also be tracked.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: American Breast Laser Ablation Therapy Evaluation (ABLATE): Monitoring the Long Term Safety and Efficacy of Novilase™ Breast Interstitial Laser Therapy in Real World Application
Study Start Date : December 2008
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Primary Outcome Measures :
  1. To monitor and measure long term safety and effectiveness Novilase [ Time Frame: ongoing ]
  2. To help refine, improve and/or validate breast tumor best practices and standard of care [ Time Frame: ongoing ]
  3. To help establish uniform and standardized imaging, pathological assessment and ablation timing protocols [ Time Frame: ongoing ]
  4. To support the medical and patient communities through transparency--by contributing and publishing relevant, useful and meaningful data to support the development and design of future research [ Time Frame: ongoing ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing Novilase for the treatment of benign breast conditions at Novian Health affiliated breast centers.

Inclusion Criteria:

  • Diagnosis confirmed by needle core biopsy
  • Tumors detected either by physical exam or imaging
  • Tumors do not exceed 2 cm in diameter and measure at least 0.5 cm away from the skin and chest wall
  • Single, multiple and/or bilateral tumors
  • Patient has given consent prior to being treated with Novilase™

Exclusion Criteria:

  • Patient is pregnant or lactating
  • Hypercellularity suggestive of phyllodes
  • Atypia
  • Equivocal pathology report (e.g., discordance between radiographic and microscopic results)
  • Fibroadenomas with stromal solidarity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00807924

Layout table for location contacts
Contact: Marti DeLay 312-266-7200 info@novianhealth.com
Contact: Eugene Bajorinas 312-266-7200 info@novianhealth.com

Layout table for location information
United States, New York
Columbia University Medical Center - Department of Surgery Recruiting
New York, New York, United States, 10032
Contact: Margaret Chen, M.D.    212-305-9676      
Principal Investigator: Margaret Chen, M.D.         
Sub-Investigator: Sheldon Feldman, M.D.         
Sub-Investigator: Bret Taback, M.D.         
Sub-Investigator: Preya Ananthakrishnan, M.D.         
Sponsors and Collaborators
Novian Health Inc.
Layout table for investigator information
Principal Investigator: Barbara Schwartzberg, MD Rose Medical Center - Rose Breast Center
Additional Information:
Layout table for additonal information
Responsible Party: Novian Health Inc.
ClinicalTrials.gov Identifier: NCT00807924    
Other Study ID Numbers: BR001
First Posted: December 12, 2008    Key Record Dates
Last Update Posted: September 9, 2020
Last Verified: September 2020
Keywords provided by Novian Health Inc.:
Minimally invasive
Interstitial laser therapy
Laser ablation
Breast lesion
Breast tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Fibroepithelial
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial